|
1.Thomlinson, R.H., Gray, L.H. The Histological Structure of Some Human Lung Cancers and the Possible Implications for Radiotherapy. Br. J. Cancer. 1955; 5: 539-549. 2.Hockel M, Schlenger K, Mitze M, Scha¨ffer U, Vaupel P. Hypoxia and radiation response in human tumours. Semin Radiol Oncol 1996; 6: 3-9. 3.Vaupel, P., Schlenger, K. knoop, C. et al. Oxygenation of Human Tumors: Evaluation of Tissue Oxygen Distribution in Breast cancers by Computerized O2 Tension Measurements. Cancer Res. 1991; 51:3316-3322. 4.Hockel M, Schlenger K, Knoop C and Vaupel P. Oxygentation of carcinomas of the uterine cervix: Evaluation by computerized O2 tension measurements. Cancer Res 1991; 51:6098-6102. 5. Kallinowski F, Zander R, Hoeckel M and Vaupel P. Tumor tissue oxygentation as evaluated by computerized-pO2-histography. Int J Radiation Oncology Biol 1990; 19:953-961. 6.Stone, H.B. Brown, J.M. Philips, T.L. and Sutherland, R.M. Oxygen in human Tumors: Correlation’s between methods of Measurement and Response to Therapy. Rad Res. 1993; 136:422-434. 7.Garrecht BM, Chapman JD. The labeling of EMT-6 tumors in BALB/C mice with 14C-misonidazole. Br J Radiol 1983; 56:745-753. 8.Hoffman JM, Rasey JS. Binding of the hypoxia tracer 3H- misonidazole in cerebral ischaemia. Stroke 1987; 18:168-176. 9.Webster LT. Drug used in chemotherapy of protozoal infections. In: Gilman AG, Rall TW, Niles AS, Taylor P, eds. The pharmacological basis of therapeutics, 8th edn. New York: Pergamon; 1990; 1002-1004. 10.Adrian Nunn, Karen Linder, H.William Strauss, Nitroimidazoles and imaging hypoxia, Eur J Nucl Med 1995; 22:265-280. 11.Chapman JD, franko AJ. A marker for hypoxic cells in tumors with potential clinical applicability. Br J Cancer 1981; 43: 546-550. 12.Biskupiak JE, Grierson JR, Rasey JS et al. Synethesis on an (iodovinyl) Misonidazole derivative for hypoxia imaging. J Med Chem 1991; 34:2165-2168. 13.Mannan RH, Somayaaii VV et al. Radioiodinated 1-(5-iodo-5’-deoxy-D-arabinofuranosyl)-2-nitronidazole (iodoazomycin arabinoside:IAZA): a novel marker of tissue hypoxia. J Nucl Med 1991; 32: 1764-1770. 14.S.H. Yeh, L.C. Wu, R.S. Liu, D.J. Yang, S.H. Yen, T.W. Yu, ‘Fluorine-18 fluoromisonidazole ([F-18]-FMISO) tumor: muscle retention ratio in detecting hypoxia in nasopharyngeal carcinoma ‘, NPCC 1992-1997 15.R.S.Liu, S.H.Yeh, W.Y.Guo, D.H.C.Pan, L.S.Lee, L.S.Chu, C.P.Chang, J.K.Wang, and L.C. Wu, Detection of cerecral hypoxia in arteriovenous malformation (AVM) by [F-18]fluorodeoxyglucoses(FMISO) ,NPCC 1992-1997. 16.R.S.Liu, S.H.Yeh, C.P.Chang, J.K.Wang, L.C.Wu, K.L.Chou, C.W.Chang, H.M. Lin, and L.S. Lee,’[F-18] fluoromisonidazole PET scan in meningioma’, NPCC 1992-1997 17.S.H. Yeh, R.S. Liu, H.H. Hu, C.P. Chang, L.s. Chu, K.L. Chou, and L.C. Wu, ’Ischemic penumbra in acute stroke: demonstration by PET with Fluorine-18 fluoromisonidazole’, NPCC 1992-1997 18.Rasey JS, Koh WJ, Evans ML, et al. Quantifying regional hypoxia in human with positron emission tomography of [18F]fluoromisonidazole: a pretherapy study of 37 patients.International Journal of Radiation Oncology, Biology, Physics. 1996; 36: 417-428. 19.Jason S Lewis, Deborah W. McCarthy et al, evaluation of 64-Cu-ATSM In Vitro and In Vivo in a Hypoxic Tumor Model. J Nucl Med 1999; 40: 177-183. 20.Philip J. Blower, Jason S. Lewis et al, Copper Radionuclides and Radiopharmaceuticals in Nuclear Medicine. Nucl Med&Bio 1996; 23 : 957-980. 21.Deborah W. McCarthy, Laura A. Bass, Michael J. Welch et al, High Purity production and Potential Applications of Copper-60 and Copper-61. Nucl Med&Bio, 1999; 26: 351-358,. 22.Ballinger JR, Kee JWM, Rauth AM. In vitro and in vivo evaluation of a technetium-99m-labelled 2-nitromidazole (BMS181321) as a marker of tumor hypoxia. J Nucl Med 1996; 37: 1023-1031. 23.Cook GJR, Barrington S, Houston S, Maisey MN, Fogelman I. HL91, a new Tc-99m-labelled agent with potential for identifying tumor hypoxia: correlation with FDG PET. J Nucl Med 1996; 37: 87P-88P. 24.Brauers G, Archer CM, Burke JF. The chemical characterization of the tumor imaging agent 99mTc-HL91. Eur J Nucl Med 1997; 24: 943. 25.Cook GJR, Houston S, Barrington SF, Fogelman I. Techne-tium-99m-labelled HL91 to identify tumor hypoxia: correlation with fluorine-18-FDG. J Nucl Med 1998; 39: 99-103. 26.林正憲 陳浩然 林次郎 徐成芳。有機配位子PnAO-NI與HL91之合成與鑑定。核能研究所對內報告。中華民國八十八年五月。 27.United States Patent, patent number: 5997843;Date of patent:Dec. 7, 1999. 28.J. Takahashi, M. Kato-Azuma 29.Bennett, M.B.: the treatment of stage III squamous carcinima of the cervix in air and hyperbaric oxygen. Br. J. Radiol. 1978; 51:68. 30.Berry, G.H., Dixon, B., Ward, A.J.: The Leeds resultsfor radiotherapy in HBO for carcinoma of the head and neck. Clin. Radiol. 1979; 30:591-592. 31.Churchill-Davidson, I., Sanger, C., Thomlinson, R.H.: High-pressure oxygen and radiotherapy. Lancet 1995;1: 1091. 32.Dische, S.: Hyperbaric oxygen: The medical research council trials and their clinical signficance. Br. J. radiol. 1979; 51: 888-894. 33.Adrian Nunn,Karen Linder,H.William Strauss,’Nitroimidazoles and imaging hypoxia’,Eur J Nucl Med 1995; 22:265-280. 34.Paula Lindholm,Heikki Minn,Sirkku Leskinen-Kallio,Jorgen Bergman,Ulla Ruotsalainen and Heikki Joensuu,’Influence of the Blood Glucose Concentration on FDG Uptake in Cancer —A PET study. J Nucl Med 1993:34:1-6 35.Koh WJ, Bergman KS, Rasey JS, et al. Evaluation of oxygenation status during fractionated radiotherapy in human nonsmall cell lung cancers using [F-18] fluoromisonidazole positron emission tomography. International Journal of Radiation Oncology, Biology, Physics. 1995; 33: 391-398. 36.Griffin RJ, Makepeace CM, Hur WJ, et al. Radiosensitization of hypoxic tumor cells in vitro by nitric oxide. International Journal of Radiation Oncology, Biology, Physics. 1996; 36(2): 377-83 37.Ha SW, Yi CJ, Cho CK, et al. Enhancement of radiation effect by Ginkgo biloba extract in C3H mouse fibrosarcoma. Radiotherapy & Oncology. 1996;41(2):163-7. 38.Griffin RJ, Okajima K, Barrios B, et al. Mild temperature hyperthermia combined with carbogen breathing increases tumor partial pressure of oxygen (pO2) and radiosensitivity. Cancer Research. 1996; 56(24): 5590-3. 39.McLaren DB, Pickles T, Thomson T, et al. Impact of nicotinamide on human tumour hypoxic fraction measured using the comet assay. Radiotherapy & Oncology. 1997; 45(2): 175-82. 40.Rasey JS, Grunbaum Z, Magee S et al. Characterization of radiolabeled fluoromisonidazole as a probe for hypoxic cells. Radiat Res 1987; 111:292-304. 41.Martin GV, Cerquerira MD, Caldwell JH et al. Fluoromisonidazole: a metabolic marker of myocyte hypoxia. Circ Res 1990; 67:240-244. 42.Koh W-J, Rasey JS, Evans ML. et al. Imaging of hypoxia in human tumors with 18F- fluoromisonidazole. Int J Radiat Oncol Biol Phys 1992; 22:199-212. 43.Rasey JS,Koh W-J, Grierson JR, Grunbaum Z, krohn KA. Radiolabeled fluoromisonidazole as an imaging agent for tumor hypoxia. Int J Radiat Oncol Biol Phys 1989; 17:985-991. 44.Rasey JS, Nelson NJ, Chin L, Evans ML, Grunbaum Z. Characterizatics of the binding of labeled fluoromisonidazole in cells in vitro. Radiat Res 1990; 122:301-308. 45.Casciari JJ, Rasey JS. Determination of the radiobiologically hypoxia fraction in multicellular sphereids from data on the uptake of 3H- fluoromisonidazole. Radiat Res 1995; 141:28-36. 46.Vaupel P, Schlenger K, Knoop C, Vaupel P. Oxygenation of carcinomas of the uterine cervix: evaluation by computerized O2 tension measurements. Cancer Res 1991; 51:6098-6102. 47.Kavanagh M-C, Sun A, Hu-Q, Hill RP. Cpmparing techniques of measuring tumor hypoxia in different murine tumors: Eppendrof pO2 histograph, 3H-misonidazole binding and paired survival assays. Radiat Res 1996; 145: 491-500. 48.Chapman JD, Baer K, Lee J. Characteristics of the metabolism-induced binding of the misonidazole to hypoxic mammalian cells. Cancer Res 1983; 43: 1523-1528. 49.Nunn A, Linder K, Strauss HW. Nitroimidazole and imaging hypoxia. Eur J Nucl Med 1995; 22: 265-280. 50.Knox RJ, Knight RC, Edwards DI. Studies on the action of nitroimidazole drugs. The products of nitroimidazoles in a radiolytic model system. Int j radiat Oncol Biol Phys 1983; 10: 1323-1326. 51.Brown JM. Hypoxic cell radiosensitisers: Where next? Int J Radiat Oncol Biol Phys 1989; 16: 987-993. 52.Overgaard, L.J. Andersen, A.P. Jensen, R. H. et al. Misonidazole combined with split-course radiotherapy in the treatment of invasive carcinoma of the larynx and pharynx: a prelimiminary reports of the Danish Head and Neck Cancer Study(DAHANCA), Protocol 2. Acta Otolaryngol. 1982; 386: 215-220. 53.Beaman A.G. Tautz W. Gabriel T. Toome V. Studies in the nitroimidazole series I. Synthesis of azomycin A and related compounds. Antimicrobial Agents Chemother. 1968b; 469-477. 54.Boyer J.H. Nitroazoles. 1986, VCH Publ. Inc., Dearfield Beach USA. 55.Breccia A., Cavallei B. Adams G.E. Nitroimidazoles; Chemistry, pharmacology and Clinical Applications. Plenum Press, New York, 1982. 56.Cavallei B. Volpe G., Arioli V., Diena A. Synthesis and biological activity of new 2-nitroimidazole derivatives. J. Med. Chem. 1978; 21: 781-784. 57.Clarke, E.D. Goulding, K.H., Warden, P. Nitroimidazolea as Anaerobic Electron Acceptors for Xanthine Oxidase. Biochem. Pharmacol. 1982; 31: 3237-3242. 58.Archer CM, Edwards B, Kelly JD. Technetium labeled agents for imaging tissue hypoxia in vivo. Proceedings of the fourth international symposium on technetium in chemistry and nuclear medicine. 1995; 535-539 59.Mitsuaki Tatsumi, Kenji Yutani, Hideo Kusuoka, Tsunehiko Nishimura. Technetium-99m HL91 uptake as a tumor hypoxia marker: relationship to tumor blood flow. Eur J Nucl Med. 1999; 26: 91-94. 60.F. F.(Russ)Knapp, Jr. Rhenium-188- A generator-Derived Radioisotope for Cancer Therapy. Cancer Biotherapy and radiopharmaceuticals. 1998; 13; 337-349 61.Michael A. Davis, Marco Chinol. Radiopharmaceuticals for Radiation Synovectomy: Ecaluation of two Yttrium-90 Particulate Agents. J Nucl Med. 1989; 30: 1047-1055.
|